Patents by Inventor Venkata P. Palle

Venkata P. Palle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • C-pyrazole A2A receptor agonists
    Publication number: 20040198692
    Abstract: 2-adenosine C-pyrazole compounds having formula (a) and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
    Type: Application
    Filed: March 30, 2004
    Publication date: October 7, 2004
    Applicant: CV Therapeutics, Inc.
    Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle
  • C-pyrazole a2a receptor agonists
    Patent number: 6770634
    Abstract: 2-adenosine C-pyrazole compounds having formula (a) and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
    Type: Grant
    Filed: March 12, 2002
    Date of Patent: August 3, 2004
    Assignee: CV Therapeutics, Inc.
    Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle
  • N-pyrazole A2A receptor agonists
    Publication number: 20040038928
    Abstract: 2-adenosine N-pyrazole compounds having the following formula: 1
    Type: Application
    Filed: August 29, 2003
    Publication date: February 26, 2004
    Applicant: CV Therapeutics, Inc.
    Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle
  • Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
    Publication number: 20040029889
    Abstract: Novel compounds of the general formula (I): and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
    Type: Application
    Filed: July 14, 2003
    Publication date: February 12, 2004
    Inventors: Jeff A Zablocki, Prabha N Ibrahim, Kevin Shunk, Elfatih Elzein, Venkata P Palle
  • Substituted piperazine compounds
    Patent number: 6677336
    Abstract: Novel compounds of the general formula: and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
    Type: Grant
    Filed: February 22, 2001
    Date of Patent: January 13, 2004
    Assignee: CV Therapeutics, Inc.
    Inventors: Jeff Zablocki, Elfatih Elzein, Grigory Nudelman, Tim Marquart, Brent K. Blackburn, Venkata P. Palle
  • 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
    Patent number: 6642210
    Abstract: N-pyrazole substituted 2-adenosine compounds and methods for using the compounds as A2A-adenosine receptor agonists useful to stimulate mammalian coronary vasodilation for therapeutic purposes and as adjuncts in cardiological imaging.
    Type: Grant
    Filed: April 12, 2002
    Date of Patent: November 4, 2003
    Assignee: CV Therapeutics, Inc.
    Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle
  • Aralkyl substituted piperazine compounds
    Publication number: 20030176440
    Abstract: Novel compounds of the general formula: 1
    Type: Application
    Filed: February 11, 2003
    Publication date: September 18, 2003
    Applicant: CV Therapeutics, Inc.
    Inventors: Jeff Zablocki, Elfatih Elzein, Brent K. Blackburn, Tim Marquart, Prabha N. Ibrahim, Venkata P. Palle
  • Partial or full A1agonists-N-6 heterocyclic 5?-thio substituted adenosine derivatives
    Patent number: 6605597
    Abstract: N6 heterocyclic 5′ modified adenosine derivatives that are adenosine A1 receptor partial or full agonists, and as such, are useful for modifying cardiac activity, modifying adipocyte function, treating central nervous system disorders, and treating diabetic disorders and obesity in mammals, and especially in humans.
    Type: Grant
    Filed: December 3, 1999
    Date of Patent: August 12, 2003
    Assignee: CV Therapeutics, Inc.
    Inventors: Jeff A. Zablocki, Venkata P. Palle, Vaibhav Varkhedkar, Luiz Belardinelli
  • Orally active A1 adenosine receptor agonists
    Patent number: 6576619
    Abstract: Esters of N6-oxa, thia, thioxa and azacycloalkyl substituted adenosine derivatives having the following formula; wherein the compounds are selective adenosine type 1 receptor agonists that are useful for the treatment cardiovascular diseases and central nervous system disorders.
    Type: Grant
    Filed: May 24, 1999
    Date of Patent: June 10, 2003
    Assignee: CV Therapeutics, Inc.
    Inventors: Brent K. Blackburn, Chris Melville, Jeff A. Zablocki, Venkata P. Palle, Elfaith O. Elzein, Lisa Wang
  • Aralkyl substituted piperazine compounds
    Patent number: 6552023
    Abstract: Novel compounds of the general formula: and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
    Type: Grant
    Filed: February 22, 2001
    Date of Patent: April 22, 2003
    Assignee: CV Therapeutics, Inc.
    Inventors: Jeff Zablocki, Elfatih Elzein, Brent K. Blackburn, Tim Marquart, Prabha N. Ibrahim, Venkata P. Palle
  • Substituted alkyl piperazine derivatives
    Publication number: 20030064994
    Abstract: Novel compounds of the general formula: 1
    Type: Application
    Filed: September 13, 2002
    Publication date: April 3, 2003
    Applicant: CV Therapeutics, Inc.
    Inventors: Vaibhav Varkhedkar, Venkata P. Palle, Jeff Zablocki, Elfatih Elzein, Brent K. Blackburn
  • Substituted alkyl piperazine derivatives
    Patent number: 6451798
    Abstract: Novel compounds of the general formula: and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
    Type: Grant
    Filed: February 22, 2001
    Date of Patent: September 17, 2002
    Assignee: CV Therapeutics, Inc.
    Inventors: Vaibhav Varkhedkar, Venkata P. Palle, Jeff Zablocki, Elfatih Elzein, Brent K. Blackburn
  • Thiophene A2A receptor agonists
    Patent number: 6440948
    Abstract: 2-(3-,4-(substituted)-5-alkylthienyl)adenosines and the 5′-uronic acid amide analogues thereof having the following formula: are disclosed herein. Additionally disclosed are medicinal methods of treatment wherein the adenosine A2A agonist activity of the noted compounds stimulates mammalian coronary vasodilation for therapeutic purposes and for purposes of imaging the heart.
    Type: Grant
    Filed: June 20, 2000
    Date of Patent: August 27, 2002
    Assignee: CV Therapeutics, Inc.
    Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle
  • ORALLY ACTIVE A1 ADENOSINE RECEPTOR AGONISTS
    Publication number: 20020091099
    Abstract: A substituted N6-oxa, thia, thioxa and azacycloalkyl substituted adenosine derivative and a method for using the composition as an A1 adenosine receptor agonist.
    Type: Application
    Filed: May 24, 1999
    Publication date: July 11, 2002
    Inventors: BRENT K. BLACKBURN, CHRIS MELVILLE, JEFF A. ZABLOCKI, VENKATA P. PALLE, EIFATIH O. ELZEIN, LISA WANG
  • N-pyrazole A2A adenosine receptor agonists
    Patent number: 6403567
    Abstract: 2-adenosine N-pyrazole compositions having the following formula: and methods for using the compositions as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
    Type: Grant
    Filed: June 22, 1999
    Date of Patent: June 11, 2002
    Assignee: CV Therapeutics, Inc.
    Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle
  • N6 heterocyclic 8-modified adenosine derivatives
    Publication number: 20020045595
    Abstract: N6 heterocyclic 8 modified adenosine derivatives that are selective, partial or full adenosine A1 receptor partial or full agonists, and as such, are useful for modifying cardiac activity, modifying adipocyte function, treating central nervous system disorders, and treating diabetic disorders and obesity in mammals, and especially in humans.
    Type: Application
    Filed: June 14, 2001
    Publication date: April 18, 2002
    Inventors: Jeff A. Zablocki, Venkata P. Palle, Prabha N. Ibrahim, Luiz Belardenelli
  • N6 heterocyclic 5' modified adenosine derivatives
    Publication number: 20020037872
    Abstract: N6 heterocyclic 5′ modified adenosine derivatives that are adenosine A1 receptor partial or full agonists, and as such, are useful for modifying cardiac activity, modifying adipocyte function, treating central nervous system disorders, and treating diabetic disorders and obesity in mammals, and especially in humans.
    Type: Application
    Filed: June 8, 2001
    Publication date: March 28, 2002
    Applicant: CV Therapeutics, Inc.
    Inventors: Venkata P. Palle, Jeff A. Zablocki, Prabha N. Ibrahim, Vaibhav Varkhedkar, Luiz Belardinelli
  • Substituted piperazine compounds
    Publication number: 20020016463
    Abstract: Novel compounds of the general formula: 1
    Type: Application
    Filed: February 22, 2001
    Publication date: February 7, 2002
    Inventors: Jeff Zablocki, Elfatih Elzein, Grigory Nudelman, Tim Marquart, Brent K. Blackburn, Venkata P. Palle
  • Substituted alkyl piperazine derivatives
    Publication number: 20010047001
    Abstract: Novel compounds of the general formula: 1
    Type: Application
    Filed: February 22, 2001
    Publication date: November 29, 2001
    Inventors: Vaibhav Varkhedkar, Venkata P. Palle, Jeff Zablocki, Elfatih Elzein, Brent K. Blackburn
  • Aralkyl substituted piperazine compounds
    Publication number: 20010041704
    Abstract: Novel compounds of the general formula: 1
    Type: Application
    Filed: February 22, 2001
    Publication date: November 15, 2001
    Inventors: Jeff Zablocki, Elfatih Elzein, Brent K. Blackburn, Tim Marquart, Prabha N. Ibrahim, Venkata P. Palle